MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company Total Non Current Liabilities 2011-2026 | LLY
Annual Total Non Current Liabilities Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.7 B | 36.1 B | 25.8 B | 21.6 B | 24.6 B | 28.3 B | 24.8 B | 21.1 B | 18.8 B | 13.7 B | 12.7 B | 10.6 B | 8.69 B | 11.2 B | 11.2 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50.7 B | 8.69 B | 21.3 B |
Quarterly Total Non Current Liabilities Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.6 B | 43.5 B | 36.6 B | 31.1 B | 32.4 B | 24.6 B | 24.7 B | 25.9 B | 21.6 B | 21.6 B | - | 24.1 B | 24.6 B | 26.6 B | 26.1 B | 28 B | 28.3 B | 28.3 B | 28.3 B | 28.3 B | 24.8 B | 24.8 B | 24.8 B | 24.8 B | 21.1 B | 21.1 B | 21.1 B | 21.1 B | 18.8 B | 18.8 B | 18.8 B | 18.8 B | 13.7 B | 13.7 B | 13.7 B | 13.7 B | 12.7 B | 12.7 B | 12.7 B | 12.7 B | 11.2 B | 10.5 B | 10.5 B | 10.6 B | 8.69 B | 8.69 B | 8.69 B | 8.69 B | 11.2 B | 11.2 B | 11.2 B | 11.2 B | 11.2 B | 11.2 B | 11.2 B | 11.2 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.6 B | 8.69 B | 19.6 B |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
63.6 M | $ 46.2 | 4.01 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
83.9 M | $ 2.49 | 1.22 % | $ 69.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
24.6 M | $ 6.85 | 1.93 % | $ 196 M | USA |
 |
Galectin Therapeutics
GALT
|
52 K | $ 2.28 | 2.24 % | $ 146 M | USA |
 |
Galapagos NV
GLPG
|
2.41 B | $ 28.82 | 1.51 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
7.22 B | $ 8.4 | 1.51 % | $ 6.83 B |  Spain |
 |
BioNTech SE
BNTX
|
341 M | $ 94.21 | -1.35 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
254 K | $ 2.37 | 20.05 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
175 K | $ 0.82 | 3.97 % | $ 6.82 M |  Australia |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Ionis Pharmaceuticals
IONS
|
1.28 B | $ 76.34 | 1.45 % | $ 12.2 B | USA |
 |
Innate Pharma S.A.
IPHA
|
105 M | $ 1.49 | 3.83 % | $ 235 M | France |
 |
INmune Bio
INMB
|
126 K | $ 1.51 | -1.95 % | $ 37.4 M | USA |
 |
Kamada Ltd.
KMDA
|
7.06 M | $ 8.31 | 1.22 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
157 M | $ 85.92 | 3.88 % | $ 7.26 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
11.6 M | $ 12.98 | -3.53 % | $ 1.72 B | Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 23.02 | 2.98 % | $ 3.81 B | USA |
 |
Liquidia Corporation
LQDA
|
10.3 M | $ 41.73 | 3.97 % | $ 3.59 B | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.56 | 1.71 % | $ 5.86 M | Israel |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
50.3 M | $ 106.77 | 0.9 % | $ 5.36 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
MannKind Corporation
MNKD
|
219 M | $ 3.88 | 35.49 % | $ 1.19 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
69.4 M | $ 0.27 | -3.84 % | $ 660 M | Britain |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 23.63 | 0.9 % | $ 3.01 B | USA |
 |
Nanobiotix S.A.
NBTX
|
44.5 M | $ 39.36 | 13.2 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |